Soft Tissue Sarcoma

New Indication: Selinexor for Advanced Dedifferentiated Liposarcoma

2022-05-20

  • Study

    Phase II-III, multicenter, randomized, double-blind, placebo-controlled study (SEAL)
    Advanced dedifferentiated liposarcoma who received 2-5 lines chemotherapy
    Selinexor (N: 188) or placebo (N:97) twice weekly in 6-week cycles

  • Efficacy

    No difference in OS
    mPFS:2.8 vs 2.1 months, [HR:0.70 (0.52-0.95), p:0.011]

  • Safety

    Treatment related death: 4 (2.1%) vs 3 (3.1%)
    Grade >= 3 AEs with selinexor: Decreased appetite (7.5%), fatigue (6.4%), nausea (5.9%)


    • J Clin Oncol. 2022 Apr 8;JCO2101829.

    Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.

    http://doi.org/10.1200/jco.21.01829

    Reviewed by Hasan Cagri Yildirim, MD on May 20, 2022